Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD103 CAR-T in relapsed/refractory AML and MDS
NCT06680752Phase 2Recruiting
- Sponsor
- ARCE Therapeutics
- Start
- May 2025
- Primary completion
- Oct 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of ARD103 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by ARCE Therapeutics. Started May 2025; status: recruiting.
02
Drugs
ARD103
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06680752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680752.